Circulating microRNAs identify patients at increased risk of in-stent restenosis after peripheral angioplasty with stent implantation. (February 2018)

• Record Type: Journal Article
• Authors: Stojkovic, Stefan; Jurisic, Magdalena; Kopp, Christoph W.; Koppensteiner, Renate; Huber, Kurt; Wojta, Johann; Gremmel, Thomas
• Is Part Of: Atherosclerosis. Volume 269(2018)
• Page Start: 197
• Page End: 203
• Publication Date: 2018-02
• Subjects: miR-195 -- Peripheral artery disease -- In-stent restenosis -- Revascularization; miRs microRNAs -- PAD peripheral artery disease -- SMCs smooth muscle cells -- TIA transient ischemic attack -- TVR target vessel revascularization; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2018.01.020
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Background and aims: Target lesion restenosis is the most frequent complication after angioplasty and stenting for peripheral artery disease (PAD). MicroRNAs (miRs) regulate crucial pathophysiological processes leading to in-stent restenosis and thrombosis. The aim of this study was to investigate the predictive value of 11 miRs for the composite endpoint of target lesion restenosis and atherothrombotic events (primary endpoint), and target vessel revascularization (TVR, secondary endpoint) in 62 consecutive PAD patients after infrainguinal angioplasty with stent implantation. Methods: Circulating miRs were assessed using quantitative real-time polymerase chain reactions. Results: Within the 2 years of follow-up, the primary endpoint occurred in 26 patients (41.9%), and 21 patients (33.9%) underwent TVR. miR-92a and miR-195 were identified as independent predictors of the primary endpoint after adjustment for age, sex and clinical risk factors with respective HR per 1 increase of standard deviation (1-SD) of 0.55 (95% CI: 0.34–0.88, p = 0.013) and HR per 1-SD of 0.40 (95% CI: 0.23–0.68, p = 0.001). MiR-195 independently predicted TVR with HR per 1-SD of 0.40 (95% CI: 0.22–0.75, p = 0.005). Adding miR-195 to clinical risk factors improved Harrell's C-index to 0.75 (95% CI: 0.66–0.85, p = 0.03) and was superior to a model with miR-92a (C-index: 0.70, 95% CI: 0.60–0.80, p for comparison =0 .012). Assessment of both miR-92a and miR-195 had no incremental value when compared to miR-195 alone (C-index: 0.79, 95% CI: 0.69–0.88, p = 0.313). Conclusions: Circulating miR-195 predicts adverse ischemic events and TVR after infrainguinal angioplasty with stent implantation. MiR-195 could improve risk stratification after peripheral endovascular revascularizations. Graphical abstract: Highlights: Circulating miR-195 predicts adverse ischemic events in peripheral artery disease. Circulating miR-195 predicts the need for target vessel revascularization. MiR-195 could improve risk stratification of patients undergoing peripheral endovascular revascularization. MiR-195 is proposed as potentially valuable and easily accessible biomarker.